Work

A phase 1b study investigating the safety, tolerability and preliminary efficacy of HX009 in post-immune checkpoint inhibitor (CPI) therapy advanced melanoma patients.

Year: 2025

Type: conference-abstract

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e14502

Authors: Lili Mao, Yu Chen, Jing Chen, Jing Lin, Ting Ye, Faming Zhang, Lei Zhang, Peng Sun, Henry Li, Yunlong Mo, Lu Si

Institutions: Peking University Cancer Hospital, Fujian Medical University, Fujian Provincial Cancer Hospital, Wuhan Union Hospital, Huazhong University of Science and Technology

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410804456

Cites:

Cited by: 1

Related to: 10